Cholangiocarcinoma Advanced: Clinical Trials

2 trials for Cholangiocarcinoma Advanced, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Terminated 1
Phase 21Completed 1

Follow Cholangiocarcinoma Advanced: new trials by email Literature Review of Cholangiocarcinoma Advanced trials Research Report on Cholangiocarcinoma Advanced

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CT-95 in Advanced Cancers Associated With Mesothelin Expression
CT-95 - Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
Phase 1TerminatedContext Therapeutics Inc.192025-03-312026-11-05
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
nal-IRI, 5-FU, leucovorin - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic
Phase 2CompletedAIO-Studien-gGmbH1002017-10-242022-05-18

Narrower conditions

Carcinoma, Ovarian Epithelial (1)  ·  Colorectal Neoplasms (1)  ·  Mesothelioma, Malignant (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)

Broader conditions

Adenoma (1)  ·  Adnexal Diseases (1)  ·  Carcinoma (1)  ·  Colonic Diseases (1)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Gastrointestinal Diseases (1)  ·  Gastrointestinal Neoplasms (1)  ·  Genital Diseases (1)  ·  Genital Diseases, Female (1)  ·  Genital Neoplasms, Female (1)

Interventions

Fluorouracil (1)  ·  Leucovorin (1)  ·  irinotecan sucrosofate (1)

Sponsors

AIO-Studien-gGmbH (1)  ·  Context Therapeutics Inc. (1)

Countries

Germany (1)  ·  United States (1)

Top investigators

Arndt Vogel, Prof. (1)  ·  Karen Chagin, MD (1)

Results publications

PMID 38870977, PMID 40147791

NIH funding

2016 (1)